(Total Views: 585)
Posted On: 12/22/2023 11:49:18 PM
Post# of 155847
Big fan of Dr Jay, but I think he himself suggested that what happens in the short-term will be most prevalent where he & the company are concerned.
IMHO, to have a short inexpensive trial that identifies LL's role & it's MOA vs addressing specific diseases (dartboard) is most practical & could lead to many combo therapies. If it had been presented as such previously, we would all be rich by now. 600 million shares later the formula still works. We just will not be as rich.
Seems that tentative end of trial will coincide with the conclusion of Amarex arbitration. Then maybe he, you, me know enough to plot our journey. For now, we just count our blessings
IMHO, to have a short inexpensive trial that identifies LL's role & it's MOA vs addressing specific diseases (dartboard) is most practical & could lead to many combo therapies. If it had been presented as such previously, we would all be rich by now. 600 million shares later the formula still works. We just will not be as rich.
Seems that tentative end of trial will coincide with the conclusion of Amarex arbitration. Then maybe he, you, me know enough to plot our journey. For now, we just count our blessings
(3)
(0)
